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Summary
T cell populations derived from naive mice produce very small amounts of interleukin 4 (IL4)
in response to stimulation on anti-CD3-coated dishes. ILA production by such cells is mainly
found among large- and intermediate-sized T cells and is dependent upon 11,2. Injection ofanti-
IgD into mice, a stimulus that leads to striking increases in serum levels of IgG1 and IgE, causes
a striking increase in the 11,4-producing capacity of T cells. This increase is first observed
4 d afterinjection of anti-IgD. 11,4 productionby T cells from anti-IgD-injected donors is mainly
found among large- and intermediate-sized T cells. Small, dense T cells are poor producers of
11,4. The capacity ofT cells from anti-IgD-injected donors to produce IL-4 is enhanced by addition
of 11,2 and is largely, but not completely, inhibited by neutralization of in situ produced IL2.
These results indicate that the control of IL-4 production in T cells from naive and anti-IgD-
injected donors is similar. However, it is possible that a portion of the IL4-producing activity
of T cells from activated donors is 11,2 independent.
Although small T cells from naive donors have a very limited capacity to produce IL4 in
response to stimulation with anti-CD3, even in the presence of added IL-2, they can give rise
to IL4-producing cells upon in vitro culture on plates coated with anti-CD3 if both IL2 and
IL-4 are added. This leads to the appearance of IL4-producing cells within 2 d. When analyzed
after 5 d of culture by harvesting and re-exposure to anti-CD3-coated culture wells and 1172,
these cells have increased their IL-4-producing capacity by -100-fold. The development of 11'4-
producing cells in response to anti-CD3, 1172, and IL-4 is not inhibited by interferon y (IFN-y),
nor does IFN-y diminish IL4 production by these cellsupon challenge with anti-CD3 plus IL-2.
T
he regulatory actions ofT lymphocytes are largely medi-
ated by the production of a group of potent polypep-
tides designated lymphokines (1). Among these molecules,
IL4 has been demonstrated to play an important role in the
growth and development of B lymphocytes (2) and in the
control of the process through which such cells switch to
the secretion of IgG1 (3) and IgE (4, 5). Long-term lines
of murine CD4+ T cells have been divided into those that
produce 114 but not IL-2 or IFN-y (Th2 cells) (6), and those
that produce IL-2 and IFN-T (Thl cells) . Based on their dis-
tinctive production of lymphokines, it would be anticipated
that Th2 cells would be efficient helpers for antibody responses,
while Thl cells should preferentially favor cellular immune
response. Indeed, in experimentally infected mice in which
progressive Leishmaniasis develops, antigen-specific T cell
clones producing 11,4 predominate, whereas in mice that limit
such infections, IL2-producing clones are mainly found (7,
8). These results strongly suggest that the decision as to which
lymphokines are produced is critical to the quality and pro-
tective value of an immune response.
Little is knownregarding the factors that determine whether
a given form of immunization will lead to cells that prin-
cipally produce IL2 or IL4. Indeed, in naive mice, very modest
amounts of IL -4 are produced by T cells in response to anti-
CD3 antibodies or to mitogenic lectins (9-11). Furthermore,
the T cells in naive animals capable of producing IL4 in re-
sponse to such stimulation are largely found in the low den-
sity population, suggesting that they represent cells that have
already been stimulated as a result of environmental immu-
nization (11). By contrast, IL-2 is produced by both small
and large T cells, implying that the control of production
of the two prototypic lymphokines may be quite different.
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is dependent upon the presence of IL-2 (11) .
Here, we examine the increase of IL4-producing capacity
among T cells in mice injected with antibodies to IgD, an
in vivo polyclonal activation stimulus known to lead to the
production of large amounts of IgG1 and IgE (12), Ig iso-
types whose production depends upon the presence of IL-4
(3-5, 13). We show that in such animals there is a striking
increase in T cells capable of producing 11,4 in response to
anti-CD3, and that this increase is first detected at about day
4, the last day on which injection of anti-IL4 antibodies can
block IgE responses in such mice (14). These results suggest
that induction of IL4-producing cells is critical to IgE produc-
tion in vivo and further support the concept that the regula-
tion of lymphokine production by T cells has striking bio-
logical effects.
We also examine in vitro conditions required for high den-
sity (small) T cells, which are very poor IL-4-producing cells,
to develop into cells that can be stimulated to produce this
lymphokine. Swain et al. (9) have reported that acquisition
of IL4-producing capacity does occur in cultures of stimu-
lated mouse T cells, and were the first to suggest that primed
but not resting T cells can produce IL4. We demonstrate
here that 11,4-producing cells can be derived in vitro, in
2-3 d, from small T cells by stimulation with anti-CD3 in
the presence ofboth IL-2 and IL4. Neither lymphokine alone
will act as a cofactor with anti-CD3 for induction of cells
capable of producing IL4. This induction appears to be highly
efficient, leading to an -100-fold increase in IL4-producing
capacity. The presence of IFN-'y during this induction period
does not block generation of IL-4-producing T cells, a some-
what surprising result in view of the effect of IFN-y in
preventing the outgrowth of IL4-producing T cell clones
in vitro in response to stimulation with antigen and IL2 (15).
Materials and Methods
Animals.
￿
Virus-free BALB/c female mice, 8-12 wk of age, were
obtained from Division of Cancer Therapy Animal Program, Na-
tional Cancer Institute, Bethesda, MD.
Culture Medium.
￿
RPMI 1640 (Biofluids, Rockville, MD) sup-
plemented with 10% FCS (HyClone Laboratories, Logan, UT),
L-glutamine (2 mM), sodium pyruvate (1 mM), 2-ME (0.05 mM),
Hepes (10 mM), penicillin (100 U/ml), and streptomycin (100
P,g/ml) was used for culturing cells.
Preparation of T Cells.
￿
Cell suspensions were prepared from
lymph nodes ofuntreated mice or mice that had been injected with
800 wg of anti-IgD 5 d earlier. The cells were washed two times
in HBSS and suspended at 4°C for 1 h with a mixture of fluores-
cence (Fl)'-conjugated antibodies containing 10 Rg/ml of anti-
B220 (6B2) and anti-lad (MKD6). At the end of the incubation,
the cells were washed twice in staining buffer and mixed for 1 h
at 4°C with a suspension of magnetic beads coated with sheep
anti-Fl antibodies (Advanced Magnetics Inc., Cambridge, MA)
(12 ml/108 stained cells). Positively staining cells were depleted by
two 20-min cycles ofexposure to a magnetic field. The remaining
cells were washed twice in culture medium and examined for the
removal of the B cells by cytometric analysis on a FACScan (Becton
' Abbreviation used in this paper. Fl, fluorescence.
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Dickinson & Co., Mountain View, CA). In general, residual B cell
content was <1%.
Fractionation of Large and Small T Cells.
￿
T cells from lymph
nodes were layered onto a discontinuous Percoll (Pharmacia Fine
Chemicals, Uppsala, Sweden) gradient (70, 66, 60, and 50% Per-
coll) and centrifuged at 1,000 g for 20 min at room temperature.
The cells at the interface between 50 and 60% Percoll (large), 60
and 66% (medium), and 66 and 70% (small) werecollected, washed
twice with HBSS, and resuspended in culture medium.
Lymphokines and Cytokines.
￿
Human rIIr2 was a gift of Cetus
Corp. (Emeryville, CA). 9,2 activity was defined in terms of"Cetus
Units". 1 Cetus U is is equivalent to -0.3 ng and to 6 WHO
IU. Synthetic IL3 was a gift o£ Dr. Ian Clark-Lewis (Biomedical
Research Center, Vancouver, Canada). 1 U of IIr3 was defined as
the amount of IL3 that stimulated half-maximal ['H]thymidine
incorporation by FD.C/1 cells. Mouse rlIr4 was obtained from a
baculovirus expression system, utilizing a vector into which the
114 gene had been inserted by C. Watson, Laboratory of Immu-
nology, MAID, Bethesda, MD. 114 activity was measured using
the CT4S cell line (16), comparing it with a standard that had
initially been calibrated on the basis of 10 U/ml being equal to
the amount of 114 required for half-maximal stimulation of
['H]thymidine uptake by resting B cells stimulated with 5 ug/ml
ofgoat anti-IgM antibody (2, 17). 1 U is equal to -0.5 pg of pro-
tein. Mouse rIFN-y was a gift of Genentech, Inc., South San Fran-
cisco, CA. Mouse rID5 was expressed in a baculovirus system,
utilizing a vector into which the IL5 gene had been inserted by
C. Watson, D. Kunimoto, and G. Harriman, MAID.
Igs and mAbs.
￿
The following antibodies were prepared by a
combination ofammonium sulfate precipitation, DE52 ion exchange
chromatography, and Sephadex G200 gel filtration (18); anti-IL2
(S4.B6) (19); anti-CD3 (2C11) (20); anti-B220 (6B2) (21); and anti-
Iad (MKD6) (22). Purified Ig was fluoresceinated with FITC, as
previouslydescribed (23). Purified monoclonal rat anti-mouse IL4
(11B11) (24) was prepared by Verax Corporation (Hanover, NH).
Affinity-purified goat anti-mouse IgD antibody was prepared as
previously described (18).
Measurement ofLymphokine Productionfrom Cells Stimulated by Plate-
Bound Antibodies. Flat-bottomed 96-well microtiter Immulon 2
plates (Dynatech Laboratories, Inc., Alexandria, VA) were coated
by incubation for 4 h at room temperature with purified anti-CD3
antibody (2C11; 10 wg/ml in 50 w1 borate buffered saline, pH 8.5).
Wells were washed threetimes with 200,ul HBSS. Cellswere added
to the antibody-coated wells(in triplicate) in 0.2 ml culture medium.
After 36 h in culture, the plates were exposed to 1000 rad in an
irradiator (Gamma Cell 40; Atomic Energy of Canada Ltd., On-
tario, Canada). Lymphokine-dependent lines (CTEV [16], an IIr2-
dependent line, or CT4S, an 11,4-dependent line) were then added
(5,000 cells/well) to measure the secretion of the individual lym-
phokines (11, 25). 48 h later, 1 pCi of ['H]thymidine (ICN, Ir-
vine, CA) was added, and after 10 h the cells were harvested.
Incorporation of tritium was measured in a liquid scintillation spec-
trometer. Relative SEs for triplicates had a mean value of 15% or
less. The amount oflymphokinewas expressed as either the quan-
tity of ['H]thymidine incorporated into the DNA of the indicator
cell line or as the equivalentof the amount of lymphokinerequired
to support the same level of thymidine incorporation in the indi-
cator cell line (equivalent units).
IL content of the supernatant of activated cells was assessed by
adding 5,000 cells from each of the appropriate cell linesto super-
natant of one well (CTEV for IL-2; CT4S for 11,4; FD.C/1 [26,
27], an 11,3-dependent line, for IL3). The extent of IL secretion
was determined by incorporation of ['H]thymidine as described
Interfeukin 2 and 4 Are Needed to Generate Interleukin 4-Producing Cellsearlier in this section. IFN-y was assayed by its ability to inhibit
plaque formationby vesicular stomatitus virus on L929/2G1 cells.
The levelof 11,5 in the supernatants wasdetermined by an ELISA
with two anti-IIL5 mAbs (28). We thank Dr. Robert Coffman
(DNAX Institute of Molecularand Cell Biology, Palo Alto, CA)
for making these measurements.
Generation offI,4producing TCellsIn Vitra
￿
SmallTcells from
lymph nodes of naive mice were incubated on anti-CD3-coated
tissue culture dishes (2-3 x 105 cells/5-cm dish) in 3 ml culture
medium alone or in culture medium supplemented with lym-
phokines and/or antilymphokine antibodies as specified in the
legends. After 3 d in culture, 2 ml of fresh culture medium and
the appropriate lymphokines and/or antilymphokine antibodies were
added. 2dlater, thecells were collected, washed three times with
HBSS, and resuspended in culture medium to further test their
IL4-producing capability on anti-CD3-coated wells. In such ex-
periments, a series of concentrations of live cells were tested for
IL-4-producing capacity. Comparisons between groups therefore
representcomparisons ofIL4-producingcapacityby specifiednum-
bers of living cells.
Results
T Cellsfrom Mice Injected with Anti-IgD Antibody Produce
More 11,4 than T Cellsfrom NaiveMice. T cells from naive
mice produce small amounts of 11,4 in response to stimula-
tion with anti-CD3 coated on the surface of culture wells.
Polyclonal stimulation by injection ofanti-IgD causes striking
increases in serum IgE in 7-8 d that can be inhibited by treat-
ment of these mice with anti-IL-4 antibody, administered as
late as 4 d afterinjection of anti-IgD (14) . These results indi-
cate that 11,4 is critical to the elevation of serum IgE that
occurs in these mice and suggest that induction of IL-4-
producing capacity occurs in such animals. We have previ-
ously shown that freshly isolated T cells from anti-IgD-injected
mice secrete small amounts of 114 without in vitro stimula-
tion (29) . To determine whether this polyclonal stimulation
resulted in an increase in the capacity of mice to produce IL-4
in response to anti-CD3 coated on culture dishes, lymph node
T cells were prepared from mice that had not been injected
with anti-IgD and from mice injected 2, 4, 6, 8, and 11 d
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￿
Low density T cells
from anti-IgD-injected donors are
better 11,4 producers than high
density T cells. T cells were pre-
pared from mice that had been in-
jected with anti-IgD 5 d earlier.
The cells were separated on Percoll
density gradients into cells of low,
intermediate, and high density.
The separated cells were cultured
in wells coated with anti-CD3 in
the presence of 11,2 and IIA
production measured as described
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in Fig. 1.
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earlier with 800 Ag of anti-IgD. Since we have shown that
the capacity of T cells from naive donors to produce IL4
in response to anti-CD3 requires the presence of IL-2 (11),
human 1172 (50 U/ml) was added to all cultures, Fig. 1 A
shows a striking increase in IL-4-producing capacity oflymph
node T cells from anti-IgD-injected donors that peaks be-
tween 4 and 6 d afterinjection. In Fig. 1 B, the IL4-producing
capacity of T cells from naive donors and from donors in-
jected with anti-IgD 5 d earlier is compared in detail. 5,000
T cells from anti-IgD-injected mice produce more IL4 in
response to anti-CD3 plus IL2 than 100,000 T cells from
naive donors, indicating that the polyclonal activation known
to lead to IgE production is marked by a striking increase
in the IL4 producing capacity of the lymph node T cell
population.
71,4producing TCellsfrom Primed Donors Have LowandIn-
termediate Densities. High density T cellsfrom naive donors
produce very little IL4 in response to anti-CD3 and 11,2,
even in the presence of exogenous accessory cells. The 11,4-
producing cellsfrom these mice are markedly enriched in the
low density T cell population (11). Similarly, IL4-producing
T cells from anti-IgD-injected donors are concentrated in cells
oflow and intermediate density (Fig. 2). Purified T cells were
Figure 1.
￿
Anti-IgD injection causes an in-
crease in T cell production of IIJ4 in response
to anti-CD3. (A) T cells were prepared from
mice that had been injected with 800 tcg of
anti-IgD 2, 4, 6, 8, and 11 d earlier and from
mice that had not been injected with anti-IgD
(day 0). Cells were cultured, in the presence
of 11,2 (50 U/ml), at 5,000/well on culture
plates that had been coated with anti-CD3.
Cultures were irradiated (1,000 rad) at 36 h,
and 5,000 CT4S cells were added. After 48 h,
[3I-11thymidine was added, and incorporation
into DNA was measured 10 h later as an
index of IL4 production. (B) In a separate ex-
periment, cells obtained from mice injected
with anti-IgD 5 d earlier or not injected were
cultured in various numbers, in the presence
of IL2, in wells coated with anti-CD3. CT4S
10'
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￿
Neutralization of 11,2 diminishes 11,4 production by T
cells from mice injected with anti-IgD. T cells were prepared from
mice that had been injected with anti-IgD 5 d earlier and cultured
on wells that had been coated with anti-CD3. IL-2 (50 U/ml),
anti-mouse 11,2 (S4.B6 [10 14g/ml]), anti-mouse 1162 plus a 1:100 di-
lution of a mixture of ascitic fluids of the anti-11,2R mAbs 3C7,
7134, 2E4, and PC61, or nothing was added to wells. 11,4 production
was measured as described in Fig. 1, except that the results are ex-
pressed as "equivalent units" rather than as uptake of [3H]thymidine.
Equivalent units represents the amount of IL-4 added to CT4S cells
that gives [3H]thymidine uptake equivalent to that observed in the
CT4S coculture assay. Since 11,2 at 50 U/ml, but not at lower con-
centrations, enhances responses of CT4S cells to ILA the dose-
response curve that was used to calculate equivalent units for the
group to which IL-2 had been added was derived from responses of
CT4S cells to which 114 had been added in the presence of 50 U/ml
of 11,2, while the dose-response curve used to calculate equivalent
units for the other groups was derived from responses of CT4S cells
to which IL4 was added in the absence of 11,2.
fractionated by Percoll density gradient centrifugation into
low density (50-60% Percoll), intermediate density (60-66%),
and high density (>66%) populations. High density cells pro-
duced very little IL4 in response to anti-CD3 in comparison
with low and intermediate density cells (Fig. 2). In these ex-
periments, IL-2 was added to all cultures to maximize ILA
production. These results indicate that among T cells from
recently stimulated mice, just as was true of T cells from
naive donors, the majorIL4-producing cell population is made
up ofcells of low and intermediate density. Since resting cells
are found mainly in the high density population, it would
appear that the small resting T cell populationin polyclonally
activated as well as in naive donors has very limited capacity
to produce ILA in response to anti-CD3.
IL4 Production by T Cells From Anti-IgD-injected Mice Is In-
hibited by Neutralization ofIL2. IL4 production by T cells
from naive donors cultured on anti-C133-coated plates is en-
hanced by the addition of 11,2 and completely inhibited by
the addition of the monoclonal anti-mouse IL-2 antibody
S4.B6 (11). The latter result indicates that in situ production
of IL2 is normally required for IL4 production by cellsfrom
naive donors stimulated with anti-CD3. To examine whether
T cells that had been "activated" in vivo as a result of injec-
tion of anti-IgD also required 11,2 in order to produce IL4,
lymph node T cells from such donors were cultured, in varying
numbers, in wells coated with anti-CD3. These cells pro-
duced substantial amounts of 11,4 (Fig. 3). In this experi-
ment, the results are reported in terms of "IL-4 equivalent
units" rather than [3H]thymidine uptake by CT4S cells,
sinceIL-2, at 50 U/ml or more, increases the response ofCT4S
cells to ILA (16). IL4 equivalent units were calculated from
dose-response curves carried out in the presence or absence
of exogenous human rIL2 (50 U/ml), as appropriate.
IL-4 production by T cells from anti-IgD-injected donors,
cultured on anti-CD3-coated wells, is substantially enhanced
by the addition ofhuman IL2 . On the other hand, the addi-
tion of the monoclonal anti-mouse IL-2 antibody S4.136, at
10,ug/ml, significantly, but incompletely, inhibits IL4 produc-
tion by T cells cultured in anti-CD3-coated wells in the ab-
sence of exogenous IL-2. This degree of inhibition was only
slightly increased by using a mixture of anti-IL2 with four
independent antibodies to the p55 chain of the IL-2R (7134,
3C7, 2E4, and PC61) (Fig. 3). These results indicate that
a major component of IL-4 production by T cells from "re-
cently activated" donors is dependent upon the presence of
IL-2. This is particularly striking when one compares IL-4
production in the presence of exogenous 11,2, to maximize
ILA production, with that in the presence of antibodies that
neutralize endogenous 11,2. 5,000 of the former cells pro-
duce more IL4 than 40,000 of the latter. Whether the re-
sidual productionofIL-4 in the presence of anti-IL-2 and anti-
p55 represents an IL-2-independent response or is due to the
difficulty of fully blocking the action of endogenously pro-
duced IL-2 is not clear.
High Density T Cellsfrom Naive Donors Contain Precursors
that Can Be Stimulated to Develop into RA-producing Cells. The
ability of T cells from primed donors to produce substan-
tially more IL4 than T cells from naive animals in response
to anti-CD3 plus IL2 suggests that the unprimed cell popu-
lation contains cells that, under appropriate in vivo condi-
tions, give rise to expanded numbers of IL4-producing cells.
Since high density T cells from naive and anti-IgD-injected
mice have very little capacity to produce IL4, the develop-
ment of IL4-producing cells from this population would be
particularly striking. Thus, we sought in vitro conditions
that would allow the appearance of IL4-producing cells from
the high density T cell population of naive donors. We ob-
served that culturing these cells for 5 d on anti-CD3-coated
dishes together with IL-2 and IL4 led to the appearance of
a cell population that produced large amounts of IL-4 in re-
sponse to anti-CD3 plus IL-2 (Fig. 4) . Thus, we observed
that 312 cells primed in vitro produced more IL-4 than did
20,000 high density cells from naive donors. This in vitro
primed T cell population was the richest source ofILA produc-
tion that we have observed, exceeding that of T cells from
anti-IgD-injected donors.
Both 11,2 and IL4 were essential for the appearance of cells
that could produce ILA in response to restimulation with
anti-CD3 plus 11,2. A priming culture of high density T
cells from naive donors with anti-CD3 plus IL-2 and mono-
clonal anti-114, to neutralize any IIJ4 that was produced en-
dogenously, did not result in the emergence of cells that could
produce IL-4 in response to anti-CD3 plus IL2 (Fig. 5 A).
Similarly, cells cultured with anti-CD3 plus IL-4 and anti-
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Figure 4.
￿
In vitro culture of dense T cells with anti-CD3 plus IL2
and 11,4 causes a striking increase in I1,4-producing capacity. T cells
from naive donors were separated by Fercoll density gradient centrifu-
gation. The dense cells (2 x 105) were cultured in a 5-cm dish that
had been coated with anti-CD3, in the presence of 3 ml of culture
medium containing IL-2 (50 U/ml) and 11,4 (1,000 U/ml). After 3 d
of culture, 2 ml of lymphokine-containing medium was added. At 5 d,
the cells were harvested and transferred to 96-well culture plates that
had been coated with anti-CD3 and cultured in the presence of IL2.
11,4 production was measured as described in Fig. 1. Dense T cells
from naive mice were freshly prepared and cultured in 96-well plates
coated with anti-CD3 at the same time as the cells that had been
cultured for 5 d were harvested and recultured.
11,2 antibody also failed to produce IL4 in the secondary cul-
ture. If the monoclonal anti-IL4 antibody was not included
in the group cultured with anti-CD3 plus IL2, little or no
IL4 was produced in the second culture, presumably because
high density T cells produce very little IL4 in response to
anti-CD3 plus IL2 in the primary culture. By contrast, if
anti-IA was not added to cellscultured with anti-CD3 plus
IL4, this cell population did give rise to IL4-producing T
cells (data not shown). This is consistent with the capacity
of high density T cells to produce IL2 in response to culture
Figure 5.
￿
Small, dense T cells
cultured with anti-CD3 plus 11,2
and IL4 give rise to IL4-producing
cells. (A) Dense T cells from naive
mice were cultured, as described in
Fig. 4, for 5 d on dishes coated
with anti-CD3 with the addition of
no lymphokine, of 11,2 (50 U/ml)
plus 11,4 (1,000 U/ml), of 11,2 plus
anti-11,4 (111111; 10_ _
￿
Kg/ml) or of
+n.-z
￿
IL4 plus anti-IL2 (54.136; 10
ug/ml). The cells were then har-
vested and tested for 114-producing
capacity by culture, in the presence
of IL2, in 96-well plates coated
with anti-CD3. (B) Dense T cells
from naive mice were cultured as in
A, except that the dishes had not
been coated with anti-CD3. I1,4-
producing capacity was measured by culture, in the presence of 11,2, in 96-well plates coated with anti-CD3. (C) Dense T cells that had been
cultured for 5 d on anti-CD3-coated culture dishes in the presence of IL2 and IL4 were transferred to 96-well plates that had been coated with
anti-CD3 or had not been coated. The cells were then cultured in the presence or absence of 11,2 (50 U/ml), and IL4 production was measured.
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with anti-CD3 and, as shown in Fig. 6 A, with the finding
that relatively small amounts of exogenous IL2 in primary
cultures with anti-CD3 and IL A are sufficient to permit the
appearance of IA-producing cells. Anti-CD3 was essential
during the first culture. Cells cultured in IL2 plus IL4, or
in IL2 or IL-4 alone, failed to produce 1164 upon secondary
culture with anti-CD3 plus IL2 (Fig. 5 B) .
The requirement of anti-CD3 plus IL2 and IL4 could not
be explained by improved cell yields, as the number ofliving
cells were essentially the same in groups cultured with anti-
CD3 plus IL2 or IL4 as they were in the group cultured
with anti-CD3 plus IL2 and IL4 (data not shown). In addi-
tion, IL4-producing capacity is expressed in terms of IL4
PRIMARY CULTURE:ANMCD3 + IL-2 + IL-4
SECONDARY CULTURE: AS INDICATED
Figure 6.
￿
Concentrations of IL2 and 114 required for induction of
114-producing T cells. Dense T cells from naive donors were cul-
tured on anti-CD3-coated culture dishes. (A) Experiments in which
1,000 U/ml of 11,4 and variable amounts of human I1 .2 were added
to dishes. Anti-mouse I1,2 (S4.B6) was added to these cultures to
neutralize endogenously produced IL2. (B) Experiments to which 50
U/ml of IL2 and varying amounts of 114 were added to culture
dishes. After 5 d of culture, cells were harvested and transferred to
96-well plates that had been coated with anti-CD3 and cultured in
the presence of IL2 to determine I1,4-producing capacity. A and B il-
lustrate results from different experiments.
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In the secondary culture, the IL4-producing cells showed
requirements for stimulation of lymphokine production similar
to that of T cells from both naive and anti-IgD-injected donors.
Anti-CD3 alone did elicit IL-4 production, but the addition
of exogenous IL2 markedly enhanced 11,4 production (Fig.
5 C). In other experiments (data not shown), monoclonal
anti-IL2 antibody diminished the production of IL4 in re-
sponse to anti-CD3 alone, indicating that the in vitro primed
cells retain a substantial dependenceon IL-2 for IL4 production.
Relatively small amounts of IL-2 are required during the
priming culture with anti-CD3 and IIA Thus, in the pres-
ence of anti-CD3 and 1,000 U/ml of IL4, 0.4 U/ml (120
pg/ml) of humanIL2 gave a definite induction of cells capable
of producing IL4 upon subsequent culture with anti-CD3
and IL2 (Fig. 6 A) . In these experiments, endogenously pro-
duced murine IL-2 was neutralized with the monoclonal
anti-mouse 1172 antibody AM. In the presence of 50 U/ml
of human IL-2, 100 U/ml of IL-4 (ti50 pg/ml) has some in-
ducing activity, but there is a dose-dependent increase with
1,000 U/ml being much more effective.
RequirementsforInduction ofIIr4producing Cells.
￿
Our ex-
periments thus far have all utilized a protocol in which dense
T cells from lymph nodes of naive donors are cultured on
plates coated with anti-CD3 plus IL-2 and IL-4 for a period
of 5 d, and are then removed from these plates and restimu-
lated with anti-CD3 plus IL2. We examined two additional
aspects of this process: the time required for this induction
and the capacity of IFN-y to inhibit it. Fig. 7 presents two
experiments in which cells were cultured with anti-CD3, 1172,
and IIA for periods of <5 d. Exp. A compares 3 d ofpriming
with 5 d. In that experiment, the cells harvested at the end
of a 3-d priming culture are quite similar to cells harvested
at 5 d in their capacity to produce IIA and are considerably
superior to the cells that had been tested without such precul-
ture (day 0 cells) or to cells cultured without IL2 or 114
(data not shown). Exp. B shows that induction of IL-4-
producing cells can also be achieved within 2 d, indicating
that the process of inducing IL4-producing cells from a resting
Figure 7. Anti-CD3 plus 11,2 and 11,4
increase 1164-producing capacity of T cells
within 2 d. Dense T cells from naive
donors were cultured in 5-ml culture dishes
coated with anti-CD3 in the presence of
11,2 (50 U/ml) and 11,4 (1,000 U/ml) for 3
or 5 d (Exp. A) or 2 or 3 d (Exp. B). At
the end of the initial culture period, the
cells were harvested and transferred to 96-
well plates that had been sensitized with
anti-CD3. Secondary cultures were carried
out in the presence of 11,2. Results are ex-
pressed as equivalent units, since secondary
assays were not carried out at the same
105
￿
time. Dose-response curves used for calcula-
CELLSIWELL
￿
tion of equivalent units were performed in
parallel with the CT4S coculture assay.
DAY 0
T cell population is a relatively rapid one if the stimulatory
conditions are correct.
IFN-y has been reported to inhibit the growth of clones
of T cells that produce IL4 in response to stimulation with
antigen, APC, and IIA (15). To test the effect of IFN-y during
the in vitro priming of lymph node T cells with anti-CD3
plus IL2 and IL4, we added IFN-y to these cultures and
compared the IL4 producing capacity of the cells that were
obtained. Fig. 8 A shows that 100 U/ml of IFN-y added
to the priming culture has little or no effect on the appear-
ance of cells that can produce IIA in response to subsequent
culture with anti-CD3 plus 11,2. 500 U/ml has a modest
inhibitory activity. Furthermore, addition of IFN-y (250
U/ml) during the elicitation phase of the culture also failed
to prevent IIA production (Fig. 8 B). These results indicate
that IFN-y does not have a profound effect on the appear-
ance of IL4-producing cells in the anti-CD3 plus IL2 and
IL4 system described here.
Discussion
T cells from naive donors stimulated with anti-CD3 ad-
sorbed onto culture wells produce little IL4. In the presence
of IL-2, IL4 production is substantially enhanced, but this
production is found mainly in cells of low and intermediate
density. High density cells, which contain small resting T
cells, produce very little IL4, even in the presence of IL2
and with supplementationby accessory cell populations (11).
Swain et al. (9) had previously reported that resting normal
T cells were poor IL4-producers. They had concluded that
IL4-producing capacity was a property of primed T cells.
The poor IL4-producing capacity of dense T cells from
naive donor stimulated with anti-CD3 are somewhat at odds
with a recent report by Carding et al. (30) using in situ hy-
bridization to detect IL4 mRNA. Those studies indicated
that 30-80% of T cells, from naive donors, stimulated with
PWM, Con A, or PHA are positive for IL4 mRNA. On
the other hand, Cardell and Sander (31) have reported a fre-
quency of cells expressing IIA mRNA in response to anti-
CD3 or to Con A of 0.5-1%. We have recently developed
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Figure 8.
￿
IFN-'y does not prevent the appearance of IL4-producing
cells, nor does it block their production of IL4. (A) Dense T cells
from naive donors were cultured for 5 d on dishes coated with anti-
CD3 in the presence of IL2 (50 U/ml) and IL4 (1,000 U/ml). IFN-'Y
was added to a final concentration of 0, 500, or 1,000 U/ml. At the
end of the 5-d culture period, the cells were harvested and cultured
on 96-well plates that had been coated with anti-CD3. IL2 was
added to secondary cultures. (B) Cells harvested from initial cultures,
described in A, that had been carried out in the presence of anti-CD3,
IL2, and IL4 were tecultured in anti-CD3-coated wells in the pres-
ence of IL2 with or without IFN-'Y (250 U/ml).
a limiting dilution assay to enumerate IL4-producing cells
(Seder et al., manuscript in preparation) . Using this approach,
we find that the frequency of T cells from lymph nodes of
naive donors that produce IL4 in response to anti-CD3 plus
IL2 is N1:1000. It should also be pointed out that studies
of recently primed mice have shown that among antigen-
primed T cells, IL4 producers are rare, although they increase
in number upon repetitive stimulation in vitro (10).
In this manuscript, we demonstrate that in vivo polyclonal
activation of mice by injection of anti-IgD antibodies strik-
ingly increases the capacity of lymph node T cells to produce
IL4 in response to anti-CD3 plus IL2. This is in keeping
with the increase in serum IgE levels in such animals (12)
and with the demonstration that treatment of these mice with
mAbs to IL4 (13) or to the IL4R (32) completely inhibits
this increase. Indeed, we have previously shown that anti-IL4
antibody treatment is effective in inhibiting the IgE response
to anti-IgD when administered as late as the fourth (but not
fifth) day after injection (14) . The observation that increased
IL4 production by T cells from anti-IgD-injected donors is
first observed on day 4 is consistent with the time course
of sensitivity to anti-IL4. It indicates that the control of in-
duction of IL4-producing capacity is critical to the increase
in IgE that occurs in certain forms ofimmunization. We have
also observed that infection withNippostrongylus brasiliensis,
which causes a striking increase in serum IgE, causes a similar
increase in T cell production of IL4 (Le Gros et al., unpub-
lished observations).
IL4 production by T cells from anti-IgD-injected donors
has many features in common with IL4 production by T
cells from naive donors. It is mainly a property of low and
intermediate density T cells, and IL2 plays a very important
role in IL4 production. When anti-CD3-treated T cellsfrom
naive donors are treated with monoclonal anti-IL2 antibody
(S4.B6), IL4 production is not detectable (11). Treatment of
T cells from anti-IgD-injected donors with S4.B6 causes a
marked inhibition of IL4 production, particularly when one
compares IL4 productionin anti-CD3-treated cells that have
received exogenous IL2 with anti-CD3-treated cells to which
anti-IL2 has been added. Nonetheless, a portion of the IL4
response by T cells from anti-IgD-primed donors is not in-
hibited by anti-IL2. This may reflect an IL2-independent com-
ponent of IL4 production that develops with time after
priming. Indeed, the fact that T cell lines of the Th2 type
produce IL4 in response to anti-CD3, mitogens or antigens
in the absence of exogenous IL2 strongly suggests that cer-
tain cells can produce IL4 without the need for IL2 (33) .
Although dense T cells from naive donors have very limited
capacity to produce IL4 in response to anti-CD3 plus IL2,
they contain cells that develop into IL4 producers. Indeed,
Swain et al. (9) have reported that stimulation of T cells from
naive donors with mitogens and T cell supernatants leads
to the appearance of cells capable ofproducing IL4 upon sub-
sequent culture. Our results demonstrate a striking appear-
ance of cells that can produce IL4 in response to anti-CD3
plus IL2 as a result of culture for 2-5 d in wells coated with
anti-CD3 to which both IL2 and IL4 have been added. Both
lymphokines are required; culture with anti-CD3 plus IL2
and anti-IL4 antibody or culture with anti-CD3 plus IL4
and anti-IL2 antibody does not yield any increase in IL4-
producing capacity, although cell yields and viability are quite
similar in all three groups. Direct comparisonofIL4-producing
capacity of dense T cells from naive donors and T cells that
have been primed in vitro by 5-d culture with anti-CD3 plus
IL2 and IL4 shows that the latter cells are almost 100 times
more active than the former. Seder et al. (manuscript in prep-
aration) have recently shown that the frequenry of IL4-pro-
ducing cells in these populations increases by a comparable
degree.
This system provides an in vitro approach for the study
of the events that regulate development of cells into IL4
producers. One obvious question is whether stimulation with
anti-CD3 plus IL2 and IL4 causes "uncommitted" cells to
differentiate into cells that can produce IL4, or whether it
causes the proliferation of cells already capable of producing
IL4 in response to anti-CD3 plus IL2. Although the evi-
dence available is not decisive, we favor the idea that cells
that can produce IL4 in response to anti-CD3 plus IL2 in
the dense T cell population from naive donors are not the
precursors (or the sole precursors) of the cells that produce
IL4 that appear after culture with anti-CD3 plus IL2 and
IL4. Our major reason for this is that the IL4-producing
capacity of the dense T cell population from naive donors
is very meager and, as our unpublished work has shown, IL
4-producing cells are very rare. Thus, these cells would have
to proliferate in preference to other cell types that are being
stimulated to proliferate by anti-CD3 plus lymphokines. While
it is certainly possible that such proliferation could explain
the appearanceof IL4 producers in a 5-d period, the fact that
they can be observed in as few as 2 d suggests that it is more
likely that the cells have differentiated from precursors that
do not, themselves, produce IL4 in response to anti-CD3plus 11,2. Whether those cells are committed to making 114
or can differentiate in other ways can best be addressed by
limiting dilution progenitor analyses.
Finally, it is important to point out that crosslinking the
TCR in the presence of IL2 and 114 is unlikely to be the
only means through which IL4 producing cells may be in-
duced. This is particularly so since 114-producing cells are
rare among naive T cell populations. Thus, in initial priming
for a response dominated by I14-producing cells, 114 may
not be available in the location or in the amounts required
for the induction we have observed. We have recently shown
that mast cells can produce IL4 (34, 35), and we have reported
the existence of a population of splenic and bone marrow
cells, lacking B and T cell markers, that express high affinity
Fce receptors and produce IL4 in response to the crosslinkage
of such receptors (25). These cells are a potential source of
114 for the priming system described here. However, IL3
is required for substantial 11,4 production in response to Fce
receptor crosslinkage on non-B, nonT cells (36) . Thus, in
unstimulated animals, the non-B, nonT pool is not a strong
candidate for a source of IL4 for priming small T cells to
develop into IL4-producing cells. Indeed, non-B, nonT cells
from naive donors are relativelypoor producers of IL4 when
compared with non-B, nonT cells from anti-IgD-injected or
Nippostrongylus brasiliensis-infected mice.
Another reason to suggest that the anti-CD3 plus IL2 and
11,4 model is not the only way through which IIL4-producing
cells can be induced is the finding that IFN-y blocks the ap-
pearance of IL4-producing cell lines in response to stimula-
tion with antigen, APC, and IL2 (15). By contrast, IFN-y
does not inhibit the generation of114-producing cells in the
anti-CD3 plus IL2 and 114 system, nor does it inhibit 11,4
productionby such T cellsin response to anti-CD3 plus IL2.
We would suggest that the induction of IL4-producing
cells from precursors in response to receptor crosslinkage plus
IL-2 and 1174 couldbe important in situations in which some
IL4-producing T cells had already been induced. Based on
the characteristics of T cell clones isolated from chronically
infected mice (7, 8), it appears that responses tend to be domi-
nated by T cells that produce IL-2 or T cells that produce
114. This "polarization" ofresponse at leastin the direction
of IL4-producing cells could represent a positive "feedback"
regulation resulting from the presence of substantial amounts
of 114 at the time that newly emerging T cells initially en-
counter antigen, particularly an antigen to which the im-
mune system was chronically exposed. Indeed, it has recently
been reported that treatment of Leishmania major-infected
BALB/c mice with anti-I14 antibody attenuates infection in
these animals and diminishes levels of 114 mRNA in lymph
nodes draining sites ofinfection (37). This suggests that IL4
may be important, in vivo, in appearance or persistence of
IL-4-producing cells.
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